Oral presentation highlights the synergistic effect of high-dose nitric oxide (NO) in combination with antibiotics in the treatment of drug-resistant mycobacterium abscessus lung infection
Dr. Abdi Ghaffari, Ph.D., Vice President of Research at Beyond Air presented data at an oral presentation entitled, “High Efficacy of High-dose Nitric Oxide and its Synergistic Effect with Antibiotics against Mycobacterium Abscessus” at the 2019 ERS Congress being held on September 28 – October 2, 2019 in Madrid, Spain.
Dr. Ghaffari’s presentation highlighted in vitro data demonstrating the potential synergistic effect of combination Amikacin or Clofazimine with high-dose (250ppm) Nitric Oxide (NO) in the treatment of drug resistant mycobacterium abscessus (M. abscessus). M. abscessus is an emerging species of multidrug-resistant nontuberculous mycobacteria (NTM) with increasing prevalence in patients with underlying pulmonary disease.
“The data demonstrating a synergistic effect between nitric oxide and antibiotics in drug-resistant M. abscessus clinical strains is an exciting step forward in the potential treatment of multidrug-resistant nontuberculous mycobacteria (NTM),” said Dr. Ghaffari. “We look forward to continuing to build upon these data with intermittent NO exposure mimicking our anticipated human clinical protocols.”
This research was conducted at Dr. Kenneth Olivier’s Laboratory of Chronic Airway Infection, Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health in Bethesda, Maryland.
Beyond Air, Inc. announced that Steven Lisi, CEO, will participate at the two upcoming conferences. Details are as follows:
Oppenheimer Fall Summit
Date: September 23, 2019
Location: Parker New York Hotel, NYC
Format: Available for 1×1 meetings
Beyond Air, Inc. announced that Steven Lisi, CEO, will participate in the 21st Annual H.C. Wainwright Global Investment Conference being held on September 8-10, 2019 at the Lotte New York Palace Hotel in New York City.
Beyond Air, Inc. announced that it has changed its NASDAQ ticker symbol from AITB to XAIR. The change is effective July 15, 2019.
- Announces name change to Beyond Air™
- Completed uplisting to the NASDAQ and $7.96 million PIPE financing
- Anticipate PMA submission in the third quarter of calendar 2019
- Anticipate CE Mark in the first half of calendar 2020
- Announced licensing agreement with Circassia Pharmaceuticals for commercial rights for hypoxic respiratory failure in the hospital setting in the United States and China
- Strengthened management team with key hires
- Conference Call scheduled for June 25 at 4:30 pm Eastern Time
AIT Therapeutics, Inc. announced it will report financial results for its fiscal year ended March 31, 2019 after the market close on Tuesday, June 25, and will host a conference call and webcast at 4:30 pm Eastern Time.
AIT Therapeutics, Inc. announced that it has successfully executed funding agreements to raise $8 million through a private investment in public equity (PIPE) financing. AIT will issue 1.6 million unregistered shares of common stock to investors at a purchase price of $5.00 per share. Proceeds from the raise will be used to continue development of the company’s three indications: Persistent Pulmonary Hypertension of the Newborn (PPHN), Bronchiolitis (BRO), and Nontuberculous mycobacteria (NTM), as well as for general corporate purposes.
“I would like to thank those who have taken the time to investigate what we at AIT have created over the past 30 months with our proprietary nitric oxide generator and delivery system technology and to understand the significant value creation for both patients and shareholders that will come with our continued execution over the next 18 months,” said Steve Lisi, Chairman and CEO of AIT. “This transaction will provide the funds needed to achieve our goals over the next 12 to 15 months of a PMA submission/FDA approval decision for PPHN, completion of our bronchiolitis trial this winter and the commencement of our at-home study in patients suffering from NTM lung infection.”
AIT Therapeutics, Inc. announced that Steven Lisi, CEO, will participate at the Jefferies 2019 Global Healthcare Conference being held at the Grand Hyatt in New York on June 4-7, 2019.
AIT Therapeutics, Inc. announced the study, authored by Professor Lea Bentur, Director, Pediatric Pulmonary Institute, Rambam Medical Center, Haifa Israel, entitled, “Pilot study to test inhaled nitric oxide in cystic fibrosis patients with refractory Mycobacterium abscessus lung infection,” was published in the Journal of Cystic Fibrosis.
“We achieved our goal of demonstrating the safety and tolerability of inhaled nitric oxide in cystic fibrosis patients with Mycobacterium abscessus lung infection and determined that further evaluation is warranted given the improvement shown in mean lung function, quality of life, physical function and M. abscessus load as shown by a downward trend in the sputum M. abscessus load measured during the study,” said Dr. Lea Bentur. “The study was not powered to demonstrate statistical significance, but we believe intermittent NO at 160ppm has the potential to demonstrate meaningful benefits to patients with cystic fibrosis where currently M. abscessus is an incurable chronic infection in most CF patients.”
AIT Therapeutics, Inc. presented data from its study: “On-Demand Nitric Oxide for Ventilator-Based Nitric Oxide Inhalation: A Risk-Reduction Perspective.” The study was presented as part of a session on pulmonary hypertension at the International Society for Aerosols in Medicine (ISAM) 2019 Congress in Montreux, Switzerland.
“This study clearly shows the safety benefits of on-demand NO and we believe our ventilator-compatible Nitric Oxide Generator and Delivery System is the way of the future,” said Steve Lisi, Chairman and CEO. “Eliminating the need for high-pressure NO cylinders in the hospital setting can bring tangible benefits, and we look forward to providing hospitals with a cost-effective, risk-reducing solution.”
AIT Therapeutics, Inc. announced that Steven Lisi, CEO, will participate in the Oppenheimer MedTech Day being held at the Hilton Union Square hotel in San Francisco on May 29, 2019.
AIT Therapeutics, Inc. announced it presented data from its study, entitled: “Synergistic Effect of Nitric Oxide with Antibiotics Against Mycobacterium Abscessus in Vitro” at the 2019 American Thoracic Society (ATS) Conference being held on May 17-22, 2019 in Dallas, TX. The study was presented today, May 20, as part of a mini-symposium on “Advances in the Treatment of NTM.”
AIT announced that the Company’s common shares have been approved for listing on the The Nasdaq Capital Market. Trading is expected to begin on Tuesday, May 7 under its existing symbol AITB.
“I would like to thank the Nasdaq team for allowing us to trade on their prestigious, globally recognized and trusted exchange,” said Steven Lisi, Chairman and Chief Executive Officer of AIT Therapeutics. “I am very proud of the team at AIT for getting us to this point and I am confident that we will continue to execute our strategy and launch our first product in the United States before the middle of 2020.”
AIT Enters into $32.5 million Commercial Licensing Agreement with Circassia Pharmaceuticals for Its Novel Nitric Oxide Generator and Delivery System for Use in the Hospital Setting in the United States and China
AIT Nearing Definitive Agreement to License Commercial Rights of Its Novel Ventilator Compatible Nitric Oxide Generator and Delivery System for Use in the Hospital Setting in the United States and a Second Country